Etrasimod
≈ 2 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Etrasimod, sold under the brand name Velsipity, is a medication that is used for the treatment of ulcerative colitis. It is a selective sphingosine-1-phosphate (S1P) receptor modulator that modifies the activity of the immune system. It is taken by mouth. The most common side effects include lymphopenia (low levels of lymphocytes) and headache. Etrasimod was discovered by Arena Pharmaceuticals, with subsequent development by Pfizer. Etrasimod was approved for medical use in the United States in October 2023, and in the European Union in February 2024.
Etrasimod, sold under the brand name Velsipity, is a medication that is used for the treatment of ulcerative colitis. It is a selective sphingosine-1-phosphate (S1P) receptor modulator that modifies the activity of the immune system. It is taken by mouth. The most common side effects include lymphopenia (low levels of lymphocytes) and headache. Etrasimod was discovered by Arena Pharmaceuticals, with subsequent development by Pfizer. Etrasimod was approved for medical use in the United States in October 2023, and in the European Union in February 2024.
Medical uses
Etrasimod is used for the treatment of moderate to severe ulcerative colitis.
Mechanism of action
It works by causing T cells to become trapped in the lymph nodes, preventing them from entering the bloodstream, from where they would travel to other tissues in the body and mediate inflammation.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1370224164 under CC BY-SA 4.0; modifications have been made.